QualityStocks News - PositiveID Achieves Positive Preliminary Results for Glucose-sensing Diabetes Device

Share Article

Positive results put PositiveID on-track to move forward with development

We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development.

QualityStocks would like to highlight PositiveID Corp., a publicly traded company. PositiveID develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing, and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays.

In the company’s news today,

PositiveID Corp. announced that preliminary results from its biotransport research study with the Diabetes Research Institute (DRI) at the University of Miami demonstrate positive data for the company’s GlucoChip.

PositiveID’s GlucoChip is a glucose-sensing implantable microchip, currently under development with RECEPTORS LLC, for individuals with diabetes. The company reports that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.

“These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane,” Robert E. Carlson, Ph.D., RECEPTORS president and chief scientific officer stated in the press release.

PositiveID chairman and CEO William J. Caragol said by achieving the positive results, the company is on-track to overcoming “significant” development challenges.

“We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project,” Caragol stated.

PositiveID and partner RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system. Should they achieve continued positive results from the biocompatibility and biotransport, PositiveID will be on-track to complete development of GlucoChip.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website